The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Real-world outcomes of autoSCT for multiple myeloma in the first-line setting
In this video, Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, discusses first-line treatment options involving autologous stem cell transplant (autoSCT) for patients with multiple myeloma (MM). Dr Richter emphasizes the importance of real-world data and discusses how findings from trials can be applied in a clinical setting. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Secura Bio: Consultancy, Honoraria; Takeda: Consultancy; Oncopeptides: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau.
